Malignancies in Transplanted Patients
The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.
Neoplasms
OTHER: Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|DRUG: Switch from calcineurin inhibitor to an mTOR inhibitor
Patient survival, After inclusion, 12 months, 2 years, 3 years
Graft survival, After inclusion, 12 months, 2 years, 3 years|ImmuKnow Assay value, 12 months|Tumour progression/regression/reoccurrence, 12 months, 2 years, 3 years|Maintained switch of immunosuppression from calcineurin inhibitor to mTOR inhibitor, 3 years|Kidney function, Creatinine measure, 12 months, 2 years, 3 years
The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.